Skip to main content
    B

    Bristol-Myers Squibb Company (BMY)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $62.94
    -0.49 (-0.77%)

    Market Cap: $129.66B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Bristol-Myers Squibb Company (BMY) Financials: Revenue, Profit and Cash Flow

    Updated Oct 29, 2026. Financial statements from company filings, amounts in US dollars.

    Bristol-Myers Squibb Company reported revenue of $48.19B for the fiscal year ended Dec 31, 2025, down 0.2% from the year before. That year, net income was $7.05B with a net margin of 14.6%, operating cash flow was $14.16B and free cash flow was $12.85B. The quarter ended Sep 30, 2026 had revenue of $13.07B and net income of $2.16B.

    Revenue and Margins

    The operating margin was 20.8% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $19.43B, a compound annual rate of 10.6%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$48.19B-0.2%63.4%20.8%14.6%
    Dec 2024$48.30B+7.3%43.4%-15.5%-18.5%
    Dec 2023$45.01B-2.5%74.2%16.2%17.9%
    Dec 2022$46.16B-0.5%76.3%18.0%13.7%
    Dec 2021$46.38B+9.1%76.1%15.9%15.1%
    Dec 2020$42.52B+62.6%72.3%-21.6%-21.2%
    Dec 2019$26.14B+15.9%69.1%22.6%13.2%
    Dec 2018$22.56B+8.6%71.3%22.7%21.9%
    Dec 2017$20.78B+6.9%71.1%16.6%4.7%
    Dec 2016$19.43BN/A74.4%23.0%23.2%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, net income fell 1.4% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$48.19B$48.30B$45.01B$46.16B$46.38B$42.52B$26.14B$22.56B$20.78B$19.43B
    Cost of revenue$17.66B$27.34B$11.61B$10.95B$11.10B$11.77B$8.08B$6.47B$6.01B$4.97B
    Gross profit$30.54B$20.96B$33.40B$35.21B$35.29B$30.75B$18.07B$16.09B$14.76B$14.46B
    Research and development$9.95B$11.16B$9.30B$9.51B$10.20B$10.05B$6.15B$6.33B$6.47B$5.01B
    Operating income$10.00B-$7.49B$7.28B$8.29B$7.38B-$9.19B$5.91B$5.11B$3.45B$4.47B
    Net income$7.05B-$8.93B$8.04B$6.34B$7.01B-$8.99B$3.46B$4.95B$975.00M$4.51B
    EBITDA$13.34B$1.22B$18.20B$17.99B$18.78B$3.51B$8.41B$6.79B$6.16B$6.47B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$13.07B$12.97B$11.49B$12.50B$12.22B$12.27B$11.20B$12.34B$11.89B$12.20B$11.87B$11.48B
    Gross profit$7.37B$9.25B$7.97B$7.01B$8.15B$7.39B$7.98B$7.50B$8.67B$8.80B-$4.02B$8.13B
    Operating income$2.84B$4.03B$3.27B$1.42B$3.01B$2.27B$3.31B$480.00M$1.91B$1.56B-$11.44B$1.30B
    Net income$2.16B$3.32B$2.68B$1.08B$2.19B$1.31B$2.46B$76.00M$1.22B$1.68B-$11.91B$1.76B
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $45.11B exceeded cash and equivalents by $34.90B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$90.04B$92.60B$95.16B$96.82B$109.31B$118.48B$129.94B$34.99B$33.55B$33.71B
    Current assets$29.39B$29.78B$31.77B$27.27B$33.26B$30.19B$29.35B$17.72B$14.85B$13.70B
    Cash and equivalents$10.21B$10.35B$11.46B$9.12B$13.98B$14.55B$12.35B$6.91B$5.42B$4.24B
    Total liabilities$71.53B$76.22B$65.67B$65.70B$73.31B$80.60B$78.25B$20.86B$21.70B$17.36B
    Short-term debt$2.26B$2.05B$3.12B$4.26B$4.95B$2.34B$3.35B$1.70B$987.00M$992.00M
    Long-term debt$42.85B$47.60B$36.65B$35.06B$39.60B$48.34B$43.39B$5.65B$6.97B$5.72B
    Shareholder equity$18.47B$16.34B$29.43B$31.06B$35.95B$37.82B$51.60B$14.03B$11.74B$16.18B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$88.77B$87.63B$86.48B$90.04B$96.89B$94.68B$92.43B$92.60B$93.67B$94.65B$99.03B$95.16B
    Total liabilities$65.37B$65.31B$66.37B$71.53B$78.29B$77.19B$74.98B$76.22B$76.47B$77.58B$82.48B$65.67B
    Cash and equivalents$9.57B$8.72B$9.57B$10.21B$15.73B$12.60B$10.88B$10.35B$7.89B$6.29B$9.33B$11.46B
    Shareholder equity$23.40B$22.32B$20.07B$18.47B$18.55B$17.43B$17.39B$16.34B$17.14B$17.02B$16.49B$29.43B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 90.7% of operating cash flow. Dividends came to 39.2% of it, with no share repurchases.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$14.16B$15.19B$13.86B$13.07B$16.21B$14.05B$8.21B$7.07B$5.28B$3.06B
    Capital expenditures$1.31B$1.25B$1.21B$1.12B$973.00M$753.00M$836.00M$951.00M$1.05B$1.22B
    Free cash flow$12.85B$13.94B$12.65B$11.95B$15.23B$13.30B$7.37B$6.12B$4.22B$1.84B
    Dividends paid$5.04B$4.86B$4.74B$4.63B$4.40B$4.08B$2.68B$2.61B$2.58B$2.55B
    Share repurchases$0$0$5.16B$8.00B$6.29B$1.55B$7.30B$320.00M$2.47B$231.00M
    Investing cash flow-$4.13B-$21.35B-$2.29B-$1.06B-$538.00M-$10.86B-$9.91B-$2.00B-$66.00M$1.48B
    Financing cash flow-$10.35B$5.13B-$9.42B-$16.96B-$16.22B-$1.15B$7.62B-$3.54B-$4.08B-$2.65B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$4.18B$3.39B$1.10B$1.97B$6.31B$3.92B$1.95B$4.44B$5.59B$2.33B$2.83B$4.25B
    Capital expenditures$344.00M$305.00M$347.00M$370.00M$320.00M$361.00M$260.00M$378.00M$324.00M$262.00M$284.00M$330.00M
    Free cash flow$3.84B$3.09B$757.00M$1.60B$5.99B$3.56B$1.69B$4.06B$5.27B$2.06B$2.55B$3.92B
    Last 12 quarters

    Frequently Asked Questions About BMY

    What is Bristol-Myers Squibb Company's annual revenue?

    Bristol-Myers Squibb Company reported revenue of $48.19B for the fiscal year ended Dec 31, 2025.

    How fast is Bristol-Myers Squibb Company's revenue growing?

    Revenue was down 0.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 1.4%.

    Is Bristol-Myers Squibb Company profitable?

    Yes. Bristol-Myers Squibb Company reported net income of $7.05B for the fiscal year ended Dec 31, 2025, with a net margin of 14.6%.

    How much free cash flow does BMY generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $14.16B minus capital expenditures of $1.31B produced free cash flow of $12.85B.

    How much debt does Bristol-Myers Squibb Company have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $42.85B, short-term debt of $2.26B and cash and equivalents of $10.21B.